277 related articles for article (PubMed ID: 34359666)
1. Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
Pellat A; Cottereau AS; Terris B; Coriat R
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359666
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].
Pellat A; Wislez M; Svrcek M; Hammel P; Afchain P; André T
Bull Cancer; 2016 Oct; 103(10):880-895. PubMed ID: 27507031
[TBL] [Abstract][Full Text] [Related]
3. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review.
Pellat A; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492939
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
5. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions.
Pellat A; Cottereau AS; Palmieri LJ; Soyer P; Marchese U; Brezault C; Coriat R
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34070035
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
8. EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms.
Munker S; Vogelhuber M; Bornschein J; Stroszczynski C; Evert M; Schlitt H; Herr W; Teufel A
Z Gastroenterol; 2020 Feb; 58(2):133-136. PubMed ID: 31896137
[TBL] [Abstract][Full Text] [Related]
9. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
[TBL] [Abstract][Full Text] [Related]
11. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H; Kong G; Grozinsky-Glasberg S
Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
[TBL] [Abstract][Full Text] [Related]
12. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract][Full Text] [Related]
15. Investigation of receptor radionuclide therapy with
Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
Dasari A; Mehta K; Byers LA; Sorbye H; Yao JC
Cancer; 2018 Feb; 124(4):807-815. PubMed ID: 29211313
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of 29 cases with neuroendocrine neoplasm in the digestive system].
Liu Z; Li JQ; Tian DY; Yin XG; Zhang J; Liu G; Liang P; Bai YQ; Shen ZY; Hu X
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1084-7. PubMed ID: 24277406
[TBL] [Abstract][Full Text] [Related]
20. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
